Sterling Pharma Solutions
About Sterling Pharma Solutions
Certifications
Categories
-
Country/Region:United Kingdom
-
On CPHI since:2016
-
Certificates:4
-
Employees:1000 - 4999
Company types
Primary activities
Meet us at
CPHI Americas 2026
Pennsylvania Convention Center, Philadelphia
2 Jun 2026 - 4 June 2026
CPHI Milan 2026
Fiera Milano, Italy
6 Oct 2026 - 8 Oct 2026
Products from Sterling Pharma Solutions (5)
-
Product ADC development
More than 30 years' experience in ADC development and specialist bioconjugation services. -
Product ADC manufacturing
Sterling’s dedicated bioconjugation facility, located in Deeside, Wales, can handle a variety of batch sizes to support cGMP clinical and preclinical manufacture of antibody drug conjugates (ADCs) and bioconjugates. Through our integrated global network, we are also capable of manufacturing linker payloads... -
Product Chemistry Services
Sterling offers a range of early phase chemistry services to ensure quality, purity and efficacy at every stage in your small molecule project. These services include: Drug discovery A comprehensive service to increase the chance of success from the start. We provide close scientific collaboration and exp... -
Product Small molecule API development
At Sterling we have extensive API Development capabilities ranging from route scouting and design, through to process optimisation and full validation support, including quality by design (QbD). As a PDMO®, science is at the core of everything that we do and underpins our approach to API Development, coupl... -
Product Small molecule API manufacturing
Scalable small molecule API manufacturing, from grams to tons: Our flexible and tailored approach to API manufacturing enables us to support even the most specialised and complex project requirements. Our facilities in the UK, EU and US are equipped with state-of-the-art API manufacturing equipment to supp...
Sterling Pharma Solutions Resources (1)
-
News Sterling Pharma and MIB partner to develop low-cost route to new oral COVID drug
The new route uses a novel enzyme, cytidine aminotransferase, which would reduce the manufacturing cost of the drug
